These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information. FOSAMAX® (alendronate sodium tablets) 14 Sep 2007  Statement by Merck & Co., Inc. Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Full Prescribing Information Patient Product Information 26 May 2009  GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification 09 Jan 2009  Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45 Janumet™ (sitagliptin/metformin HCl) tablets Full Prescribing Information Patient Product Information 08 Jun 2009  Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes Januvia™ (sitagliptin) Full Prescribing Information Patient Product Information 06 Jun 2009  In Investigational Studies, New Uses of JANUVIA™ (sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes SINGULAIR® (montelukast) Full Prescribing Information Patient Product Information 12 Jun 2009  Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium) 29 May 2009  Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent 13 Jan 2009  Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast)

*Software to view files presented in PDF or SWF format is available at no charge through the Adobe Web site. Get Adobe Reader Get Adobe Flash Player

Printer Friendly Page